Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00465985 · OUTCOME

Pharmacokinetics (CLD (L/d))

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome · Source last updated 2017-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
L/day
Interval / dispersion
Standard Deviation
Time frame
48 weeks after study start

What was measured

Assessed serum clearance of ACZ885.

Analysis population: Patients in Part I and Part II who received at least one dose of ACZ885.

Groups in this outcome

ACZ885

ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ACZ88535

Reported measurements

Source class 1
Values in L/day · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
ACZ8850.1770.085Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.085
        value
        0.177
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
description
Assessed serum clearance of ACZ885.
dispersion Type
Standard Deviation
groups
  1. description
    ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.
    id
    OG000
    title
    ACZ885
param Type
MEAN
population Description
Patients in Part I and Part II who received at least one dose of ACZ885.
reporting Status
POSTED
time Frame
48 weeks after study start
title
Pharmacokinetics (CLD (L/d))
type
SECONDARY
unit Of Measure
L/day

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice